Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

NCT01870609 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

344

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis-DSMB stated good safety profile but lack of efficacy

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG: defactinib (VS-6063)
DRUG: Placebo

Sponsor

Verastem, Inc.